In GBM, receptor tyrosine kinase (RTK) gene alterations occur at high frequency, for example, more than half of GBMs showed evidence of epidermal growth factor receptor (EGFR) aberrations (19), likewise, platelet-derived growth factor receptor (PDGFR) and vascular endothelial growth factor receptor (VEGFR) were found in 40% and 39% of examined GBMs, respectively, making them attractive potential targets for therapeutic inhibition (20, 21). Here, EGFR is linked to glioblastoma.